Products Press Releases Partnering Careers Contact

Featured Post

Health Canada approves Quillivant® ER (extended release) oral suspension and chewable tablets for the treatment of ADHD.

September 25, 2023

January 5, 2022

Shield Therapeutics and KYE Pharmaceuticals Inc Announce Exclusive licence agreement for development and commercialisation of Accrufer®

June 3, 2021

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

May 4, 2021

KYE Announces Commercial Availability of CORZYNA™ (ranolazine 500 mg extended-release tablets)

January 5, 2021

KYE Pharmaceuticals Announces Approval of CORZYNA™ in Canada (ranolazine extended-release tablets)

October 28, 2020

KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE® in Canada

August 26, 2020

KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data Exclusivity